217 related articles for article (PubMed ID: 7795143)
41. Models of prophylaxis.
Berntorp E; Fischer K; Miners A
Haemophilia; 2012 Jul; 18 Suppl 4():136-40. PubMed ID: 22726097
[TBL] [Abstract][Full Text] [Related]
42. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
43. Secondary prophylaxis in adolescent and adult haemophiliacs.
Tagliaferri A; Di Perna C; Rivolta GF
Blood Transfus; 2008 Sep; 6 Suppl 2(Suppl 2):s17-20. PubMed ID: 19105505
[TBL] [Abstract][Full Text] [Related]
44. Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia.
Thornburg CD; Pipe SW
Haemophilia; 2006 Mar; 12(2):198-9. PubMed ID: 16476098
[No Abstract] [Full Text] [Related]
45. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
46. Personalized prophylaxis.
Collins PW
Haemophilia; 2012 Jul; 18 Suppl 4():131-5. PubMed ID: 22726096
[TBL] [Abstract][Full Text] [Related]
47. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia.
Croteau SE; Cheng D; Cohen AJ; Holmes CE; Malec LM; Silvey M; Thornburg CD; Wheeler AP; Kouides PA; Raffini LJ; Neufeld EJ
Haemophilia; 2019 Jul; 25(4):668-675. PubMed ID: 30993845
[TBL] [Abstract][Full Text] [Related]
48. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B.
Ahlberg A
Acta Orthop Scand Suppl; 1965; ():Suppl 77:3-132. PubMed ID: 5854304
[No Abstract] [Full Text] [Related]
49. [Prophylaxis in patients with haemophilia complicated by inhibitors].
Paweł Ł
Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
[TBL] [Abstract][Full Text] [Related]
50. Progression of haemophilic arthropathy in children: a Lithuanian--Danish comparative study.
Saulyte Trakymiene S; Clausen N; Poulsen LH; Ingerslev J; Rageliene L
Haemophilia; 2013 Mar; 19(2):212-8. PubMed ID: 23167920
[TBL] [Abstract][Full Text] [Related]
51. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
[TBL] [Abstract][Full Text] [Related]
52. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Mahdi AJ; Obaji SG; Collins PW
Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
[TBL] [Abstract][Full Text] [Related]
53. Transition considerations for extended half-life factor products.
Croteau SE; Neufeld EJ
Haemophilia; 2015 May; 21(3):285-288. PubMed ID: 25855484
[No Abstract] [Full Text] [Related]
54. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries.
Ljung R; Aronis-Vournas S; Kurnik-Auberger K; van den Berg M; Chambost H; Claeyssens S; van Geet C; Glomstein A; Hann I; Hill F; Kobelt R; Kreuz W; Mancuso G; Muntean W; Petrini P; Rosado L; Scheibel E; Siimes M; Smith O; Tusell J
Haemophilia; 2000 Nov; 6(6):619-24. PubMed ID: 11122385
[TBL] [Abstract][Full Text] [Related]
55. Use of prophylaxis to prevent complications of hemophilia.
Mannucci PM; Mendolicchio L; Gringeri A
Adv Exp Med Biol; 2001; 489():59-64. PubMed ID: 11554591
[No Abstract] [Full Text] [Related]
56. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed.
van Dijk K; Fischer K; van der Bom JG; Grobbee DE; van den Berg HM
Haemophilia; 2005 Sep; 11(5):438-43. PubMed ID: 16128885
[TBL] [Abstract][Full Text] [Related]
57. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy.
Fischer K; van der Bom JG; Mauser-Bunschoten EP; Roosendaal G; Prejs R; Grobbee DE; van den Berg HM
Haemophilia; 2001 Sep; 7(5):446-52. PubMed ID: 11554930
[TBL] [Abstract][Full Text] [Related]
58. Cost effectiveness of haemophilia treatment: a cross-national assessment.
Lippert B; Berger K; Berntorp E; Giangrande P; van den Berg M; Schramm W; Siebert U;
Blood Coagul Fibrinolysis; 2005 Oct; 16(7):477-85. PubMed ID: 16175006
[TBL] [Abstract][Full Text] [Related]
59. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
Lindvall K; Astermark J; Björkman S; Ljung R; Carlsson KS; Persson S; Berntorp E
Haemophilia; 2012 Nov; 18(6):855-9. PubMed ID: 22681244
[TBL] [Abstract][Full Text] [Related]
60. Changing pattern of care of boys with haemophilia in western European centres.
Chambost H; Ljung R;
Haemophilia; 2005 Mar; 11(2):92-9. PubMed ID: 15810909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
